Latest news with #MedicalDevices
Reuters
10 hours ago
- Business
- Reuters
China says 'dissatisfied' as EU bars Chinese firms in medical device tenders
BEIJING, June 24 (Reuters) - China is strongly dissatisfied and firmly opposes the European Union's restrictions on Chinese companies in the medical devices sector, its commerce ministry said on Tuesday. The European Commission on Friday said it will bar Chinese firms from participating in EU public tenders for medical devices worth 60 billion euros ($69 billion) or more a year after concluding that EU companies are not given fair access to the Chinese market. "The European side has persisted in using unilateral tools to build new protectionist barriers, which not only harms the interests of Chinese enterprises, but also seriously undermines fair competition," the ministry said. ($1 = 0.8617 euros)
Malaysian Reserve
25-04-2025
- Business
- Malaysian Reserve
OTC Drugs, Medical Devices and Diagnostics Market to Hit $359.7 Billion by 2029
'Rising chronic disease burden and increased health awareness are driving significant growth in the global OTC drugs, medical devices and diagnostics market.' BOSTON, April 24, 2025 /PRNewswire/ — BCC Research reveals in its new report, OTC Drugs, Medical Devices, and Diagnostics: Global Markets, the over-the-counter drugs, medical devices and diagnostics market is estimated to grow to $359.7 billion by 2029 at a compound annual growth rate (CAGR) of 7.4% for the forecast period. The rising prevalence of chronic diseases and heightened health awareness following the COVID-19 pandemic are propelling this global market. This indepth analysis categorizes OTC products by pharmaceutical drugs, vitamin and mineral supplements and various devices and diagnostics for disease management, including monitoring, therapeutic and diagnostic kits. The market is further segmented by application to include a range of health issues such as respiratory, orthopedic, gastrointestinal, cardiovascular, ENT, skin and sleep disorders, as well as diabetes and obesity. Covering a wide range of OTC products and applications, the report highlights industry advancements, relevant patents and the regulatory landscape. For instance, companies like Apple and Samsung are acquiring regulatory approvals, which could revolutionize the wearable devices sector and significantly enhance OTC disease monitoring. Factors Driving the Market: Chronic diseases and aging population: The rise in chronic disease prevalence and an aging population increase the demand for OTC drugs, medical devices, and diagnostics. Health awareness: People are more aware of health maintenance and disease prevention, driving demand for OTC products and diagnostics. Online sales and telehealth: E-commerce and telehealth platforms make healthcare products and services more accessible, boosting market growth. Request a sample copy of the OTC Drugs, Medical Devices, and Diagnostics: Global Markets report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $236.8 billion Market size forecast $359.7 billion Growth rate CAGR of 7.4% for the forecast period of 2024-2029 Segments covered Product, application Countries/Regions Covered North America, Europe, Asia-Pacific, Rest of the World — including U.S., Canada, Germany, U.K., France, Italy, Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia, Lithuania, Latvia, Hungary, Slovakia, China, India, Japan, Australia, South Korea, Singapore, Malaysia, New Zealand, Thailand, the Philippines, Vietnam, Indonesia, South America, the Middle East, and Africa Market drivers • Growing prevalence of chronic diseases and expanding geriatric populations • Increasing health awareness • Growing online sales channels and telehealth platforms Industry Facts: The U.S. FDA approved the Apple Watch's AFib feature in 2024, integrating wearable tech into clinical trials. This development revolutionizes OTC devices by empowering consumers and advancing real-time, noninvasive health monitoring for medical research. Leading global pharmaceutical companies are spinning off their consumer health businesses. This shift allows them to focus on core biopharma operations, allocate resources more effectively, adopt flexible business models, and better serve customers. The OTC drugs, medical devices, and diagnostics market is a multibillion-dollar industry. Fragmented with a mix of multinational and smaller companies, each segment has its own unique players. Emerging Startups NOWDiagnostics develops and manufactures 'Touch to Test' over-the-counter and point-of-care diagnostic tests that deliver results in minutes. The company's patented technology enables accurate onsite immunological assays using a minimal amount of capillary blood or saliva. Vitable is a health and wellness startup that offers personalized vitamin and customized supplement and vitamin packs tailored to individual needs and delivered directly to customers. Valencell plans to launch the Fingertip Blood Pressure Monitor, the world's first OTC device to measure blood pressure from the finger without a cuff. Questions Addressed: 1. What is the projected market size and growth rate of the OTC drugs, medical devices and diagnostics market? • The global OTC drugs, medical devices and diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 7.4% to reach $359.7 billion by 2029 from $251.7 billion in 2024. 2. Which segments are covered in the report? • The market is segmented based on product, application and region. 3. Which product segment will dominate the market by the end of 2029? • The OTC drugs segment will dominate the market by the end of 2029. 4. Which region has the largest market share? • North America holds the largest share. Market Leaders: Koninklijke Philips N.V. Masimo Nestle Procter & Gamble Sanofi Abbott Bayer Dsm-firmenich Haleon Group of Companies Kenvue Related Reports: Nutraceuticals: Global Markets: The report analyzes the market shares of leading companies in the nutraceuticals market. It segments the market by product type into functional beverages, food, and dietary supplements. Applications include sports and energy, weight management, general wellness, heart health, gastrointestinal (GI) and digestive health. Distribution channels are categorized by e-commerce, supermarkets, pharmacies, retail stores, and other distribution channels. Regional estimates cover North America, Europe, Asia-Pacific, and the Rest of the World. Wearable Medical Devices: Technologies and Global Markets: This research report covers the global market for wearable medical devices, segmented by product, application, and sales channel. It includes an in-depth analysis of market estimations and trends. The market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The report discusses major players, technologies, applications, market dynamics and geographic opportunities and examines analytical frameworks like PESTEL, ESG, regulatory landscape, reimbursement scenario, and competitive analysis to aid strategic planning. Directly purchase a copy of this report from BCC Research. For further information or any of these reports or to make a purchase, please contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo – View original content:
Yahoo
24-04-2025
- Business
- Yahoo
OTC Drugs, Medical Devices and Diagnostics Market to Hit $359.7 Billion by 2029
"Rising chronic disease burden and increased health awareness are driving significant growth in the global OTC drugs, medical devices and diagnostics market." BOSTON, April 24, 2025 /PRNewswire/ -- BCC Research reveals in its new report, OTC Drugs, Medical Devices, and Diagnostics: Global Markets, the over-the-counter drugs, medical devices and diagnostics market is estimated to grow to $359.7 billion by 2029 at a compound annual growth rate (CAGR) of 7.4% for the forecast period. The rising prevalence of chronic diseases and heightened health awareness following the COVID-19 pandemic are propelling this global market. This indepth analysis categorizes OTC products by pharmaceutical drugs, vitamin and mineral supplements and various devices and diagnostics for disease management, including monitoring, therapeutic and diagnostic kits. The market is further segmented by application to include a range of health issues such as respiratory, orthopedic, gastrointestinal, cardiovascular, ENT, skin and sleep disorders, as well as diabetes and obesity. Covering a wide range of OTC products and applications, the report highlights industry advancements, relevant patents and the regulatory landscape. For instance, companies like Apple and Samsung are acquiring regulatory approvals, which could revolutionize the wearable devices sector and significantly enhance OTC disease monitoring. Factors Driving the Market: Chronic diseases and aging population: The rise in chronic disease prevalence and an aging population increase the demand for OTC drugs, medical devices, and diagnostics. Health awareness: People are more aware of health maintenance and disease prevention, driving demand for OTC products and diagnostics. Online sales and telehealth: E-commerce and telehealth platforms make healthcare products and services more accessible, boosting market growth. Request a sample copy of the OTC Drugs, Medical Devices, and Diagnostics: Global Markets report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $236.8 billion Market size forecast $359.7 billion Growth rate CAGR of 7.4% for the forecast period of 2024-2029 Segments covered Product, application Countries/Regions Covered North America, Europe, Asia-Pacific, Rest of the World — including U.S., Canada, Germany, U.K., France, Italy, Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia, Lithuania, Latvia, Hungary, Slovakia, China, India, Japan, Australia, South Korea, Singapore, Malaysia, New Zealand, Thailand, the Philippines, Vietnam, Indonesia, South America, the Middle East, and Africa Market drivers • Growing prevalence of chronic diseases and expanding geriatric populations • Increasing health awareness • Growing online sales channels and telehealth platforms Industry Facts: The U.S. FDA approved the Apple Watch's AFib feature in 2024, integrating wearable tech into clinical trials. This development revolutionizes OTC devices by empowering consumers and advancing real-time, noninvasive health monitoring for medical research. Leading global pharmaceutical companies are spinning off their consumer health businesses. This shift allows them to focus on core biopharma operations, allocate resources more effectively, adopt flexible business models, and better serve customers. The OTC drugs, medical devices, and diagnostics market is a multibillion-dollar industry. Fragmented with a mix of multinational and smaller companies, each segment has its own unique players. Emerging Startups NOWDiagnostics develops and manufactures "Touch to Test" over-the-counter and point-of-care diagnostic tests that deliver results in minutes. The company's patented technology enables accurate onsite immunological assays using a minimal amount of capillary blood or saliva. Vitable is a health and wellness startup that offers personalized vitamin and customized supplement and vitamin packs tailored to individual needs and delivered directly to customers. Valencell plans to launch the Fingertip Blood Pressure Monitor, the world's first OTC device to measure blood pressure from the finger without a cuff. Questions Addressed: 1. What is the projected market size and growth rate of the OTC drugs, medical devices and diagnostics market? • The global OTC drugs, medical devices and diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 7.4% to reach $359.7 billion by 2029 from $251.7 billion in 2024. 2. Which segments are covered in the report? • The market is segmented based on product, application and region. 3. Which product segment will dominate the market by the end of 2029? • The OTC drugs segment will dominate the market by the end of 2029. 4. Which region has the largest market share? • North America holds the largest share. Market Leaders: Koninklijke Philips N.V. Masimo Nestle Procter & Gamble Sanofi Abbott Bayer Dsm-firmenich Haleon Group of Companies Kenvue Related Reports: Nutraceuticals: Global Markets: The report analyzes the market shares of leading companies in the nutraceuticals market. It segments the market by product type into functional beverages, food, and dietary supplements. Applications include sports and energy, weight management, general wellness, heart health, gastrointestinal (GI) and digestive health. Distribution channels are categorized by e-commerce, supermarkets, pharmacies, retail stores, and other distribution channels. Regional estimates cover North America, Europe, Asia-Pacific, and the Rest of the World. Wearable Medical Devices: Technologies and Global Markets: This research report covers the global market for wearable medical devices, segmented by product, application, and sales channel. It includes an in-depth analysis of market estimations and trends. The market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The report discusses major players, technologies, applications, market dynamics and geographic opportunities and examines analytical frameworks like PESTEL, ESG, regulatory landscape, reimbursement scenario, and competitive analysis to aid strategic planning. Directly purchase a copy of this report from BCC Research. For further information or any of these reports or to make a purchase, please contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio
Yahoo
20-04-2025
- Business
- Yahoo
Insiders At Abbott Laboratories Sold US$3.3m In Stock, Alluding To Potential Weakness
Over the past year, many Abbott Laboratories (NYSE:ABT) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period. While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In the last twelve months, the biggest single sale by an insider was when the Executive VP & Group President of Medical Devices, Lisa Earnhardt, sold US$2.4m worth of shares at a price of US$106 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$131. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 27% of Lisa Earnhardt's stake. Abbott Laboratories insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! Check out our latest analysis for Abbott Laboratories For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket. Over the last three months, we've seen significant insider selling at Abbott Laboratories. Specifically, insiders ditched US$886k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Abbott Laboratories insiders own 0.5% of the company, currently worth about US$1.1b based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. Insiders haven't bought Abbott Laboratories stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. But since Abbott Laboratories is profitable and growing, we're not too worried by this. It is good to see high insider ownership, but the insider selling leaves us cautious. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Abbott Laboratories. While conducting our analysis, we found that Abbott Laboratories has 1 warning sign and it would be unwise to ignore this. Of course Abbott Laboratories may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
17-03-2025
- Business
- Yahoo
Abbott Laboratories Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution
In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether. Check out our latest analysis for Abbott Laboratories The Executive VP & Group President of Medical Devices, Lisa Earnhardt, made the biggest insider sale in the last 12 months. That single transaction was for US$2.4m worth of shares at a price of US$106 each. So it's clear an insider wanted to take some cash off the table, even below the current price of US$127. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 27% of Lisa Earnhardt's stake. In the last year Abbott Laboratories insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket. The last quarter saw substantial insider selling of Abbott Laboratories shares. In total, insiders dumped US$886k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Abbott Laboratories insiders own about US$1.0b worth of shares (which is 0.5% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. Insiders sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. But it is good to see that Abbott Laboratories is growing earnings. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Abbott Laboratories has 1 warning sign we think you should be aware of. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
